

LONDON . PARIS . MUNICH . NEW YORK . GENEVA . NEW DELHI



Please find our Research on Bloomberg BRYG <GO>)

26th September 2016

	Last close	Daily chg (%)	Chg YTD (%)
Indices			
Dow Jones	18261.45	-0.71%	+4.80%
S&P 500	2164.69	-0.57%	+5.91%
Nasdaq	5305.75	-0.63%	+5.96%
Nikkei	16754.02	-0.32%	-11.98%
Stoxx 600	345.34	-0.73%	-5.60%
CAC 40	4488.69	-0.47%	-3.20%
Oil /Gold			
Crude WTI	44.28	-4.09%	+19.03%
Gold (once)	1339.71	+0.01%	+26.10%
Currencies/Rates			
EUR/USD	1.12195	-0.19%	+3.28%
EUR/CHF	1.08935	+0.21%	+0.18%
German 10 years	-0.147	-7.89%	-123.15%
French 10 years	0.15	+6.20%	-84.68%
Euribor	-0.302	+0.33%	+130.53%

Upcoming BG events

Date	
30th-Sept	Thematic Breakfast with Vimpelcom
28th-Oct	IMERYS (Paris roadshow)
14th-Nov/ 15th-Nov	4th Paris Healthcare Conference
28th-Nov/ 29th-Nov	2nd Paris Consumer Conference

Recent reports

	Date 15th-Sept	Remy Cointreau : It keeps getting better
	14th-Sept	Automotive Innovation: the only way to stand out!
	9th-Sept	ENGIE The twelve labours of Engie
	7th-Sept	FRESENIUS : ¡Salud!
	6th-Sept	WIRECARD Ready to reconnect with the fundamentals
	24th-Aug	AMS Catching the ball when it bounces - all a question of timing
L	ist of our Reco	& Fair Value : Please click here to download



BG's Wake Up Call

CASINO GUICHARD

BUY, Fair Value EUR57 (+30%)

Real Estate in Colombia (first take comment)

Éxito, Casino's subsidiary in Colombia (54,8% equity owned), and the private equity fund Fondo Inmobiliario Colombia have signed a memorandum of understanding for the capitalisation of Viva Malls by FIC. Éxito is to hold 51% of Viva Malls, while FIC is to have a 49% stake from a total cash contribution to the vehicle of over COP\$770 billion (EUR230m). FIC is to contribute with over half its total investment to the vehicle upon closing. At this stage, we estimate that a good bet could be that Exito increases its stake in GPA (which is still trading on very low multiples of around ~0.3x EV/sales).

BUY, Fair Value EUR177 (+4%)

L'Oréal still gaining market share in the UK!

Last week, L'Oréal hosted its Capital Market Days in the UK where it is the market leader with an 18.5% share after making constant market share gains (14.6% in 2006). In our view, L'Oréal UK has what it takes to reduce the gap with its market share in WE (20.5%). Buy and EUR177 FV maintained.

NESTLÉ

BUY, Fair Value CHF83 vs. CHF84 (+8%)

Deteriorating trends in China and Brazil

We revise downwards our Q3 estimate for Nestlé's organic sales growth from +5.5% to +3.5%. China is suffering from a deceleration in the food & beverage market and regulations in the infant nutrition sector, while Brazil has been penalised by a drop in volumes as a result of the group's increase in prices. Over the year, we now expect 3.7% organic sales growth, which compares to the consensus forecast for 4.2%. Our Fair Value is adjusted to CH83.

U-BLOX

BUY, Fair Value CHF255 (+14%)

Feedback from 2016 analysts' day: opportunities remain solid

On Friday, u-blox hosted an analysts' day during which the group did not spend much time on figures but was particularly talkative about technology and market opportunities. u-blox was particularly convincing about the advantages of maintaining its own proprietary LTE chip IP and investing in IoT dedicated chip designs. Discussions with management led us to believe that the group has the right position to benefit from 1/ autonomous driving and connected vehicles thanks to its leading position in this area, 2/ smart industries (professional drones, asset tracking...), 3/ smart cities with applications such as parking meters or road pricing. Overall, the presentation was convincing and perfectly in line with our main scenario. We reiterate our Buy recommendation and our FV of CHF255.

In brief...

ERYTECH, Phase II data for GRASPA in pancreatic cancer set to be released in Q1 2017 GALAPAGOS, FITZROY detailed results put the bar high

UBISOFT, Ubisoft acquires the stake held by Bpifrance (3.2% of the capital, 5.7% of the voting rights)

Food retailing

Casino Guichard

Price EUR43.77

Bloomberg				CO FP
Reuters	CASP.PA			
12-month High / L		56	.5 / 35.2	
Market Cap (EURn			4,901	
Ev (BG Estimates)			8,391	
Avg. 6m daily volu	me (000)			434.8
3y EPS CAGR				7.9%
	1 M	3 M	6 M 3	1/12/15
Absolute perf.	-4.4%	-14.8%	-12.5%	3.2%
Food Retailing	1.0%	-0.7%	-3.9%	-1.3%
DJ Stoxx 600	0.5%	-0.3%	1.5%	-5.6%
YEnd Dec. (EURm)	2015	2016e	2017e	2018e
Sales	46,145	41,237	42,725	44,156
% change		-10.6%	3.6%	3.4%
EBITDA	2,343	1,997	2,204	2,403
EBIT	968.0	1,195	1,319	1,432
% change		23.5%	10.4%	8.6%
Net income	412.0	284.3	379.5	433.0
% change		-31.0%	33.5%	14.1%
	2015	2016e	2017 e	2018e
Operating margin	3.1	2.9	3.1	3.2
Net margin	0.9	0.7	0.9	1.0
ROE	NM	NM	NM	NM
ROCE	5.2	5.3	5.9	6.3
Gearing	48.9	20.2	20.5	21.6
(EUR)	2015	2016e	2017 e	2018e
EPS	2.80	2.09	3.04	3.51
% change	-	-25.1%	44.9%	15.8%
P/E	15.7x	20.9x	14.4x	12.5x
FCF yield (%)	NM	2.6%	11.4%	9.5%
Dividends (EUR)	3.12	3.12	3.12	3.12
Div yield (%)	7.1%	7.1%	7.1%	7.1%
EV/Sales	0.3x	0.2x	0.2x	0.2x
EV/EBITDA	5.5x	4.2x	4.0x	3.9x



13.3x

FV/FBIT

Real Estate in Colombia (first take comment)

Fair Value EUR57 (+30%)

BUY

Éxito, Casino's subsidiary in Colombia (54,8% equity owned), and the private equity fund Fondo Inmobiliario Colombia have signed a memorandum of understanding for the capitalisation of Viva Malls by FIC. Éxito is to hold 51% of Viva Malls, while FIC is to have a 49% stake from a total cash contribution to the vehicle of over COP\$770 billion (EUR230m). FIC is to contribute with over half its total investment to the vehicle upon closing. At this stage, we estimate that a good bet could be that Exito increases its stake in GPA (which is still trading on very low multiples of around ~0.3x EV/sales).

Éxito, Casino's subsidiary in Colombia, and the private equity fund Fondo Inmobiliario Colombia (FIC, one of the largest private equity funds in Colombia focus on commercial real estate) have signed a memorandum of understanding for the capitalisation of Viva Malls by FIC. Viva Malls is dedicated to the development and operation of commercial real estate in Colombia under the Viva brand.

By 2016, Viva Malls will hold 320,000 sqm of GLA consisting of 10 assets currently operating and two other shopping centers scheduled to open this year. With another two assets currently under development, the vehicle will have 440,000 sqm of GLA (Gross Leasable Area) our of a total portfolio of approximately COP1.6 billion by the end of 2018

Éxito is to hold 51% of Viva Malls, while FIC is to hold a 49% stake from a total cash contribution to the vehicle of over COP\$770 billion (EUR230m). FIC would contribute, with over half its total investment to the vehicle upon closing.

ANALYSIS

- From a proportional accounting viewpoint (first take), the impact of this operation on Casino's fully loaded proportionate Net Debt / EBITDAR ratio should be limited (less than 10 bp we believe).
- From a full consolidation viewpoint (first take), this operation should have a neutral/positive impact on Éxito's EPS: 1/ the retailer will keep consolidating 100% of EBITDA (as it will own 51% of the vehicle); 2/ the minorities line of the P&L should increase; however 2/ the cash in (EUR230m) should help reduce financial costs by ~EUR16m in 2017 (10,5% estimated cost of debt) and more than compensate for the increase in minorities.
- At this stage, we estimate that a good bet could be that Exito increases its stake in GPA (which is still trading on very low multiples around 0.3x EV/sales). On the whole, we would see this operation as a good pair trade (sell real estate which yields perhaps 10/12% in favour of GPA whose upturn could offer yields well above that hopefully), which is perhaps a premise of a wider reorganisation in LatAm (see our latest report on the subject: With hindsight: a real Catch-22!).

VALUATION

Our SOTP currently stands at EUR53 per share (i.e. 21% premium on Casino share) when taking
into account EUR3011m in holding net debt (excl. seasonality), an amount which does not
include any other non-cash items which, according to slide no. 11 of the latest corporate
presentation, will have an impact (the point here is that the group neither defines nor
quantifies these non-cash items, thus creating an uncomfortable zone of uncertainty). Should
these non-cash items reach EUR500m, our spot SOTP would work out at EUR48 (10% premium
on Casino share).

NEXT CATALYSTS

Further reorganisation in LatAm

Click here to download



Analyst: Antoine Parison 33(0) 1 70 36 57 03 aparison@bryangarnier.com Sector Team: Nikolaas Faes Loïc Morvan Cédric Rossi Virginie Roumage

Luxury & Consumer Goods

L'Oréal

Price EUR169.70

Bloomberg				OR FP
Reuters				OREP.PA
12-month High	/ Low (EUR)		•	176.2 / 143.9
Market Cap (El	JRm)			95,032
Ev (BG Estimate	es) (EURm)			93,372
Avg. 6m daily v	olume (000)			562.0
3y EPS CAGR				6.0%
	1 M	3 [/]	6 1/1	21/12/15

3y EPS CAGR				6.0%
	1 M	3 M	6 M	31/12/15
Absolute perf.	-0.7%	0.7%	9.8%	9.3%
Pers & H/H Gds	-0.1%	0.9%	5.1%	2.6%
DJ Stoxx 600	2.2%	1.9%	2.2%	-4.9%
YEnd Dec. (EURm)	2015	2016e	2017 e	2018 e
Sales	25,257	26,030	27,33	2 28,561
% change		3.1%	5.09	% 4.5%
EBITDA	5,248	5,490	5,78	2 6,141
EBIT	4,388	4,610	4,88	2 5,211
% change		5.1%	5.99	% 6.8%
Net income	3,491	3,665	3,88	9 4,156
% change		5.0%	6.19	% 6.9%
	2015	2016e	2017e	2018e
Operating margin	17.4	17.7	17.	9 18.2
Net margin	13.8	14.1	14	2 14.6
ROE	13.7	14.2	13.	9 13.8
ROCE	22.4	22.6	22.	9 23.3
Gearing	-2.3	-6.7	-10.	5 -13.6
(EUR)	2015	2016e	2017 e	2018e
EPS	6.18	6.49	6.88	3 7.36
% change	-	5.0%	6.19	6.9%
P/E	27.5x	26.2x	24.7	x 23.1x
FCF yield (%)	3.1%	3.2%	3.49	6 3.5%
Dividends (EUR)	3.10	3.35	3.60	3.90
Div yield (%)	1.8%	2.0%	2.19	6 2.3%
EV/Sales	3.7x	3.6x	3.4	x 3.2x
EV/EBITDA	18.0x	17.0x	16.0	x 14.8x
EV/EBIT	21.5x	20.3x	18.9	x 17.5x



L'Oréal still gaining market share in the UK! Fair Value EUR177 (+4%)

Last week, L'Oréal hosted its Capital Market Days in the UK where it is the market leader with an 18.5% share after making constant market share gains (14.6% in 2006). In our view, L'Oréal UK has what it takes to reduce the gap with its market share in WE (20.5%). Buy and EUR177 FV maintained.

BUY

ANALYSIS

- On Thursday and Friday, L'Oréal hosted its Capital Market Days dedicated to the UK cosmetics market and the group's market share gains in the country. The UK is the world's sixth-largest cosmetics market with a value of close to GBP5m, or around 3% of the worldwide market, on our estimates. Last year, in 2015, it grew by 2.5% compared with 3.8% for the world cosmetics market. Nevertheless, it clearly outperformed the western European market that remained almost unchanged with a poor 1% increase, implying that the UK grew more than 3x faster than WE. At this point, it is worth noting that 40% of the London population is non Caucasian. The UK cosmetics market is split by 45% for the mass market, with a clear domination of Boots that together with others drugstores has a 43% market share and is still well oriented, while the classic retailers (Tesco, Sainsbury...) have a 35% market share and showed sales down 3% last year.
- In this growing market, L'Oréal is the country leader with an 18.5% market share, which is far higher than the group average (12.5%) but also lower than in western Europe (20.5%). Market share stood at 16.9% in 2014, but no more than 14.6% in 2006, thereby highlighting L'Oréal's ability to improve its competitive advantage. On average, the UK has accounted for one third of WE growth over the last five years. The UK is the group's fourth-largest country after the US, China and France. In the UK, 50% of the population has already used a L'Oréal group product, while this figure stands at 90% in France and 70% in Italy, thereby highlighting the fact that the French group still harbours upside for market share gains. In 2015, L'Oréal sales in the UK grew by 5.6% and the country was one of the best performers in this area along with Germany (+3.1%) and Spain (+3.6%). Positive momentum is still accelerating with 8% growth in H1 2016, with the upswing in performance stemming mainly from the huge success of make-up brand Nyx.
- L'Oréal's 18.5% market share in the UK is particularly strong in the mass market (20%), while it is slightly dispointing in the luxury division (17%) in which L'Oréal is the challenger as Estée Lauder is by far the leader with a 23% market share. Nevertheless, the gap between the leader is narrowing having stood at 11 points in 2006 and was no more than six points last year. In the professional products division, L'Oréal also has a very significant market share (33% which was 26% in 2006).
- E-commerce is a clear driver of L'Oréal growth in the UK. In 2015, e-commerce sales grew 24% and accounted for 7.5% of group sales but in H1 2016 (globally in 2015, e-commerce sales accounted for 5% of total group sales with a 38% increase), this segment momentum has even accelerated (there also partly thanks to Nyx) with a 33% increase and accounted for close to 9% of sales. In H1, e-commerce sales growth was even stronger in the consumer products division (+59%). This allowed the division to grow by 4.5%, 1.7x faster than the market. L'Oréal Paris is the first cosmetics brand in the UK and, paradoxically, the brand's sales in the UK are even higher than the level achieved by the brand in France! In this division, L'Oréal has grown 2.2x faster than the market on average and over the past 10 years.

VALUATION

• L'Oréal has gained 9% YTD (BDF share price remained almost unchganged) or +15% vs the DJ Stoxx. We are maintaining our Buy recommendation as we are convinced that sales momentum should accelerate in H2 (+4.9%) vs H1 (+4.4%).

NEXT CATALYSTS

Q3 sales to be reported on 3rd November.

Click here to download



Analyst : Loïc Morvan 33(0) 1 70 36 57 24 Imorvan@bryangarnier.com Sector Team : Nikolaas Faes Antoine Parison Cédric Rossi Virginie Roumage

Food & Beverages

Nestlé Price CHF76.80

Bloomberg	NESN VX
Reuters	NESZn.VX
12-month High / Low (CHF)	79.9 / 69.4
Market Cap (CHF)	239,014
Ev (BG Estimates) (CHF)	250,264
Avg. 6m daily volume (000)	5 141
3y EPS CAGR	7.9%

Avg. 6m daily volui 3y EPS CAGR	me (000)			5 141 7.9%
Jy LF3 CAGK				1.7/0
	1 M	3 M	6 M 3	1/12/15
Absolute perf.	-1.5%	6.2%	7.3%	3.0%
Food & Bev.	0.1%	2.3%	3.4%	0.4%
DJ Stoxx 600	0.5%	-0.3%	1.5%	-5.6%
YEnd Dec. (CHFm)	2015	2016e	2017 e	2018 e
Sales	88,785	89,833	93,168	98,419
% change		1.2%	3.7%	5.6%
EBITDA	17,210	17,765	18,889	20,501
EBIT	13,382	13,916	14,958	16,302
% change		4.0%	7.5%	9.0%
Net income	10,353	10,839	11,669	12,815
% change		4.7%	7.7%	9.8%
	2015	2016e	2017e	2018e
Operating margin	15.1	15.5	16.1	16.6
Net margin	117	12.1	12.5	13.0
. • • • • • • • • • • • • • • • • • • •	11.7	12.1	12.5	13.0
ROE	16.6	16.7	17.4	
o .				18.1
ROE	16.6	16.7	17.4	18.1 15.8
ROE ROCE	16.6 12.5	16.7 12.9	17.4 14.3	18.1 15.8
ROE ROCE Gearing	16.6 12.5 0.9	16.7 12.9 0.6	17.4 14.3 0.3	18.1 15.8 0.0
ROE ROCE Gearing (CHF)	16.6 12.5 0.9 2015	16.7 12.9 0.6 2016 e	17.4 14.3 0.3 2017 e	18.1 15.8 0.0 2018e 4.14
ROE ROCE Gearing (CHF) EPS	16.6 12.5 0.9 2015	16.7 12.9 0.6 2016 e 3.51	17.4 14.3 0.3 2017e 3.77	18.1 15.8 0.0 2018e 4.14 <i>9.8%</i>
ROE ROCE Gearing (CHF) EPS % change	16.6 12.5 0.9 2015 3.30	16.7 12.9 0.6 2016 e 3.51 <i>6.2%</i>	17.4 14.3 0.3 2017e 3.77 7.7%	18.1 15.8 0.0 2018e 4.14 <i>9.8%</i> 18.5x
ROE ROCE Gearing (CHF) EPS % change P/E	16.6 12.5 0.9 2015 3.30 - 23.3x	16.7 12.9 0.6 2016 e 3.51 <i>6.2%</i> 21.9x	17.4 14.3 0.3 2017e 3.77 7.7% 20.4x	18.1 15.8 0.0 2018e 4.14 <i>9.8%</i> 18.5x
ROE ROCE Gearing (CHF) EPS % change P/E FCF yield (%)	16.6 12.5 0.9 2015 3.30 - 23.3x 4.2%	16.7 12.9 0.6 2016e 3.51 <i>6.2%</i> 21.9x 4.2%	17.4 14.3 0.3 2017e 3.77 7.7% 20.4x 5.0%	18.1 15.8 0.0 2018e 4.14 <i>9.8%</i> 18.5x 5.4% 3.35
ROE ROCE Gearing (CHF) EPS % change P/E FCF yield (%) Dividends (CHF)	16.6 12.5 0.9 2015 3.30 - 23.3x 4.2% 2.25	16.7 12.9 0.6 2016e 3.51 <i>6.2%</i> 21.9x 4.2% 2.30	17.4 14.3 0.3 2017e 3.77 7.7% 20.4x 5.0% 2.35	18.1 15.8 0.0 2018e 4.14 <i>9.8%</i> 18.5x 5.4% 3.35



19.0x

18.0x

FV/FBIT

Deteriorating trends in China and Brazil

Fair Value CHF83 vs. CHF84 (+8%)

BUY

We revise downwards our Q3 estimate for Nestlé's organic sales growth from +5.5% to +3.5%. China is suffering from a deceleration in the food & beverage market and regulations in the infant nutrition sector, while Brazil has been penalised by a drop in volumes as a result of the group's increase in prices. Over the year, we now expect 3.7% organic sales growth, which compares to the consensus forecast for 4.2%. Our Fair Value is adjusted to CH83.

ANALYSIS

- Weakness in Q3. We expect 3.5% organic sales growth, in line with the H1 trend, but well below our previous estimate (+5.5%). This performance is likely to disappoint. At its H1 results publication, Nestlé indicated that organic sales growth should accelerate over the rest of the year, supposedly driven by a 1/ favourable comparison base as H2 2015 was affected by a rebate adjustment on skin health products in the US and the Maggi noodles recall, and 2/ a recovery in the pricing effect due to price increases made to offset currency depreciation. Over the year, we now expect 3.7% organic sales growth vs 4.2% previously. The group's 2016 guidance is for organic sales growth in line with 2015 (+4.2%).
- Deteriorating trends in China (8% of sales) and Brazil (4% of sales). The slowdown in the food & beverage market in China is significant and is a result of economic slowdown, reverse migration, the change in channel dynamics and very tough competition from local players. The stabilisation of Yinlu is an objective for the end of 2017. The Chinese infant nutrition market has been disrupted by new regulations, which are inducing tough price competition, mainly in the mainstream and premium segments. In Brazil, price increases in a tough economic background have caused a significant drop in volumes that was not well anticipated by the group.
- A challenged food industry. On 16th September, we trimmed our estimates for Danone due to China. Its total sales are expected to rise only 1.4% in Q3, after +4.1% in Q2, primarily due to 1/ the Water division, impacted by the deceleration in the non-alcoholic beverages market, which is now growing 0-3% vs 5-10% previously and 2/ Early Life Nutrition, with destocking of traders operating in cross border ecommerce ahead of regulatory changes.

VALUATION/RECOMMENDATION

- Our DCF now points to a Fair Value of CHF83 (CHF84 previously) as we cut our EPS estimates by 1% on average over the next three years. At yesterday's share price, the stock is trading at 21.9x P/E 2016e and 20.4x P/E 2017e, in line with the peer average.
- Nestlé was the best performing stock in our food coverage universe over the past six months. It outperformed the DJ Stoxx by 6% vs +3% for Danone and +2% for Unilever. We expect some weakness in the coming days because of consensus adjustments.
- The group's diversified profile is an asset in a challenging environment. We estimate that
 Chinese baby food only accounts for 3% of the group's EBIT vs 12% at Danone. In addition, the
 arrival of Mr Schneider should trigger a more active acquisitions policy. We maintain our Buy
 recommendation.

NEXT CATALYSTS

14.7x

16.4x

Q3 2016 sales: Unilever on 13th October, Danone on 18th October, Nestlé on 20th October,

Click here to download




Analyst : Virginie Roumage 33(0) 1.56.68.75.22 vroumage@bryangarnier.com Sector Team : Nikolaas Faes Loïc Morvan Antoine Parison Cédric Rossi

TMT

u-bloxPrice CHF224.00

Bloomberg UBXN SW Reuters UBXN.S 12-month High / Low (CHF) 246.4 / 164.0				UBXN.S
12-month High / Lo		246.4		
Market Cap (CHFm Ev (BG Estimates) (1,525 1,450	
Avg. 6m daily volu				24.30
3y EPS CAGR	110 (000)			26.8%
-,	1 M	3 M	6 M 31	1/12/15
Absolute perf.	-6.9%	6.8%	20.9%	4.4%
Semiconductors	3.3%	23.5%	26.2%	23.8%
DJ Stoxx 600	0.5%	-0.3%	1.5%	-5.6%
YEnd Dec. (CHFm)	2015	2016e	2017e	2018e
Sales	338.3	380.9	469.1	591.3
% change		12.6%	23.1%	26.0%
EBITDA	76.0	86.9	106	129
EBIT	51.3	59.5	71.7	92.5
% change		16.0%	20.5%	29.0%
Net income	37.1	44.8	57.4	75.6
% change		20.9%	27.9%	31.8%
	2015	2016e	2017e	2018e
Operating margin	15.2	15.6	15.3	15.6
Net margin	11.0	11.8	12.2	12.8
ROE	14.9	15.9	17.7	20.0
ROCE	21.8	22.4	23.2	24.7
Gearing	-26.1	-26.3	-25.1	-22.0
(CHF)	2015	2016e	2017e	2018e
EPS	5.45	6.59	8.43	11.10
% change	-	20.9%	28.0%	31.8%
P/E	41.1x	34.0x	26.6x	20.2x
FCF yield (%)	2.1%	1.5%	1.4%	1.3%
Dividends (CHF)	1.57	1.90	2.11	2.78
Div yield (%)	0.7%	0.8%	0.9%	1.2%
EV/Sales	4.3x	3.8x	3.1x	2.4x
EV/EBITDA	19.2x	16.7x	13.6x	11.2x
EV/EBIT	28.5x	24.4x	20.1x	15.6x



Feedback from 2016 analysts' day: opportunities remain solid Fair Value CHF255 (+14%)

On Friday, u-blox hosted an analysts' day during which the group did not spend much time on figures but was particularly talkative about technology and market opportunities. u-blox was particularly convincing about the advantages of maintaining its own proprietary LTE chip IP and investing in IoT dedicated chip designs. Discussions with management led us to believe that the group has the right position to benefit from 1/ autonomous driving and connected vehicles thanks to its leading position in this area, 2/ smart industries (professional drones, asset tracking...), 3/ smart cities with applications such as parking meters or road pricing. Overall, the presentation was convincing and perfectly in line with our main scenario. We reiterate our Buy recommendation and our FV of CHF255.

BUY

ANALYSIS

- Overview of the company's main focus: industry, smart cities and automotive markets. Most
 of the day concerned three applications on which u-blox is focusing: automotive, smart-cities
 and industry. The group shared details about three product categories: Positioning, Cellular and
 Short Range Connectivity.
- Positioning: the group maintains its technology leadership. In this field, the group maintains a leading position in GNSS for in-car navigation systems, asset tracking (fixed or moving) and high precision GNSS solutions for drones. While these markets remain dynamic, we also see the ublox technology perfectly fitting other applications such as agriculture, machine control, high precision mapping or even professional sport applications. The group continues to outstrip the market with innovations such as cm-level precision (the industry's first low-power and cost-efficient product) or untethered dead-reckoning (also an industry first) that fits perfectly growing applications such as Autonomous driving. Beyond the official presentation, we are particularly positive regarding u-blox' product portfolio and strategy. In our view, the group is the only player that offers both automotive and industry dedicated chips (reliability, efficiency, form-factor...) that are cost-efficient (at a >USD100 price tag). As a result, the group has a product portfolio that serves as a reference in these two growing market segments. This is not particularly new, but it worth recalling while it is also interesting to see that the group continues to maintain a technology leadership here.
 - Cellular connectivity: a right move into IoT dedicated network. While most Cellular chip makers focus on the next moves by Apple and Samsung in the Cellular field, u-blox runs in another direction: the IoT dedicated network. 2G networks are being unplugged really soon in some avant-gardist countries (U., Finland...), we might expect other countries to follow in coming years. However, 2G networks were a good support for industry connected tools (gas/water meters, payment devices and vending machines, industrial automation,...) and also automotive. So the main point is what will come next to fill the empty room. Rather than focus on high-volume, low-price and low-margin markets such as consumer applications, u-blox has a similar strategy to its positioning segment, i.e. to focus on lower volumes, high quality and highmargin markets and this explains why the group now invests in the very specific field of cellular connectivity: narrowband (low bandwith), low power chips. As a result, u-blox is highly involved in IoT dedicated LTE category: Cat 1, Cat M1 and Cat NB1. The group developed its own IP for these categories, which should provide a mid-term boost to margins (not to be expected before 2018 in our view). With this unique approach, u-blox 1/ responds to industrial clients' needs and 2/ stands out from peers such as Telit or Sierra, which use tweaked consumer chips and are dependent on technology choices of bigger cellular chip suppliers since they do not have capabilities to design and produce their own chipset, and ensure long-term support and production of each chipset (because of the dependence on their suppliers roadmap, focusing on consumer market). And, as for GNSS, the market offers multiple opportunities such as connected health, insurance, autonomous cars or asset tracking.
- Short-range connectivity: this product familly comes under the spotlight. Finally, the group spent some time on opportunities concerning short-range connectivity, namely Wi-Fi and Bluetooth. Currently, u-blox offers SR connectivity options using chips from another chip maker (we believe Nordic Semi.) but we understand that the group tries to develop its own SR connectivity IP. As for GNSS and LTE chips, u-blox will then be able to improve its margin but in the meantime, it must invest in R&D. Also, being able to integrate its own chip, the group is then able to offer a better product (stability, reliability, scalability and flexibility). Again, the group will not compete with most of the BT and Wi-Fi giants, since it will not focus on the consumer market.
- Overall, during the analysts' day, the group was particularly convincing regarding its strategy

and market opportunities. Focusing on the industry and automotive markets is really important in our view since the group manages to maintain a great stability in margins thanks to this specialisation. Following this day, we remain very confident in the group's outlook both in the short and long term. What we see in the current R&D pipeline and u-blox roadmap is really encouraging and we do not see any equivalent player in the industry. In addition, the group benefits from a unique proprietary IP, which allows it to control the evolution of the core devices used to build its modules and offers potential for margin improvement over the midterm. Note that we expect a slight improvement in EBIT margin from 2018e (2018e EBIT margin: 16% vs. 15% in 2015).

VALUATION

• Based on our estimates, u-blox shares trade at a 2016e-2017e P/E ratio of 33.5x-26.2x respectively and a 2016e-2017e PEG ratio of 1.3x-1.0x.

NEXT CATALYSTS

16th March 2017: Annual Results 2016

Click here to download document



Analyst:
Dorian Terral
33(0) 1.56.68.75.92
dterral@bryangarnier.com

Sector Team : Richard-Maxime Beaudoux Thomas Coudry Gregory Ramirez

Healthcare

ERYTechPrice EUR18.82

	Bloomberg				ERYPFP
	Reuters		ERYP.PA		
	12-month High /	Low (EUR)		34	4.5 / 18.2
	Market Cap (EUR	m)			149
	Avg. 6m daily volu	ume (000)			19.10
		1 M	3 M	6 M 3	31/12/15
	Absolute perf.	-12.7%	-8.9%	-25.8%	-26.5%
	Healthcare	0.2%	1.7%	5.9%	-6.9%
	DJ Stoxx 600	0.5%	-0.3%	1.5%	-5.6%
		2014	2015e	2016 e	2017 e
ı	P/E	NS	NS	NS	NS
ı	Div yield (%)	NM	NM	NM	NM

Phase II data for GRASPA in pancreatic cancer set to be released in Q1 2017 Fair Value EUR47 (+150%)

BUY

ANALYSIS

- Erytech announced that the last patient has been enrolled in its Phase II study evaluating ERY-ASP as a second-line treatment for pancreatic cancer in combination with gemcitabine/FOLFOX.
 Given that the primary endpoint is an improvement in progression-free survival (PFS) at four months, we understand that the readout is now expected in Q1 2017.
- The stock is likely to react positively in our view... Especially since the timing of this catalyst is confirmed, and the stock has been under pressure lately. But we would like to reiterate our cautious stance vis-à-vis this development: 1/ apart from the simple fact that the role of asparaginase has not been established for the treatment of solid tumours, and pancreatic cancer is known to be a quite challenging one; 2/ we believe that the therapeutic landscape has become more competitive in recent years (SHP's Onivyde currently setting the bar for the second-line, while CELG's Abraxane is getting a large share of the first-line). In other words, we would recommend playing this catalyst with some caution.

VALUATION

• BUY reiterated with a FV of EUR47, bearing in mind that we (still) give no value to ERY-ASP as a potential treatment for pancreatic cancer.

NEXT CATALYSTS

- Q1 2017: Phase II results of ERY-ASP as a 2L treatment for pancreatic cancer.
- H2 2017: Phase II results of GRASPA in AML + approval in refractory/relapse ALL.

Click here to download

Mickael Chane Du, mchanedu@bryangarnier.com

Healthcare

Div yield (%)

Galapagos Price EUR63.78

Bloomberg		GLPG BB		
Reuters				GLPG.BR
12-month High / L	ow (EUR)		6	3.8 / 32.7
Market Cap (EURr	n)			2,945
Avg. 6m daily volu	ıme (000)			233.0
	1 M	3 M	6 M	31/12/15
	I IVI	3 IVI	O IVI	31/12/13
Absolute perf.	31.5%	34.9%	66.8%	12.4%
Healthcare	0.2%	1.7%	5.9%	-6.9%
DJ Stoxx 600	0.5%	-0.3%	1.5%	-5.6%
	2014	2015e	2016e	2017e
P/E	NS	NS	N:	S NS

NM

NM

NM

NM

FITZROY detailed results put the bar high Fair Value EUR64 (0%)

BUY

ANALYSIS

- Galapagos has released detailed FITZROY phase II results (filgotinib in Crohn's disease). At week 10, 25% of patients achieved at least a 50% improvement in Simple Endoscopic Score for Crohn's disease (SES-CD). This compares with 13.6% for the placebo arm. These results and the timing of the release should not be overlooked.
- More physicians are considering the SES-CD score, which helps to assess mucosal healing. While the study was not powered to show statistical significance on this endpoint, we are pleased with the results as Galapagos put the bar at 50% improvement. Indeed, several companies such as Celgene set a lower threshold i.e. a 25% improvement in SES-CD score. Moreover, note that the FITZROY population was a hard one to treat with 60% of patients recruited non-responders to anti-TNF.
- Galapagos' results might put pressure on CELGENE, which stated earlier this month that only a
 proportion of patients had an endoscopic improvement. No data enables us to compare the
 two compounds on this criteria so far. However, we would note that the CELGENE trial has a
 25% threshold and that 64 patients enrolled might be short to show a meaningful clinical
 improvement.

VALUATION

· We reiterate our BUY rating

NEXT CATALYSTS

Today 2.00pmCET: conference call on detailed results (US +1 719 457 2086, UK +44 330 336 9411, FR +331 76 77 22 57; access code 8889838).

Click here to download

 $Hugo\ Solvet,\ hsolvet@bryangarnier.com$

TMT

Ubisoft

Price EUR34.31

Bloomberg		UBI.FP		
Reuters		UBIP.PA		
12-month High /	Low (EUR)		38	3.3 / 18.0
Market Cap (EUR	m)			3,855
Avg. 6m daily volu	ume (000)			249.0
	1 M	3 M	6M 3	31/12/15
Absolute perf. Softw.& Comp.	-3.2%	2.3%	24.3%	28.6%
SVS	4.3%	10.6%	11.7%	8.9%
DJ Stoxx 600	0.5%	-0.3%	1.5%	-5.6%
	03/16	03/17e	03/18e	03/19e
P/E	33.8x	28.3x	18.6x	13.5x
Div yield (%)	NM	NM	NM	NM

Ubisoft acquires the stake held by Bpifrance (3.2% of the capital, 5.7% of the voting rights)

Fair Value EUR34 (-1%)

FACTS

Friday after trading, Ubisoft announced the signing of an agreement with Bpifrance (the Banque Publique d'Investissement) for the purchase of the 3,625,178 Ubisoft shares held by Bpifrance (3.2% of the capital), at a price of EUR33.80/share i.e. a total amount of EUR122.5m. The transaction fits into Ubisoft's share buyback programme and will close by the beginning of November. The shares are to be allocated to the employee shareholding plans, the convertible bond issued through a private placement on 21st September and/or to potential external growth operations (likely in the mobile segment in our view).

ANALYSIS

- Note that Bpifrance had double voting rights, so the 3.2% stake in UBI's share capital is equivalent to 5.7% of voting rights. The Guillemot family will continue to hold 12.84% of UBI's capital and 18.91% of the voting rights, and it seems to have the support of Fidelity ~10% and Blackrock ~5%). This compares with Vivendi 22.8% and 20.2% respectively.
- The transaction is accretive to UBI's shareholders and avoids the block having to be sold on the market (i.e. no pressure on the price and no volatility). Bpifrance wanted to sell its stake but also to support Ubisoft's management until the AGM next week. The agreement signed has met these needs. As a result, nothing will happen before the shareholder's meeting (29th September), in order that Bpifrance can vote.

VALUATION

We maintain our Buy recommendation and FV of EUR34 (only based on fundamentals). The share price fully values the group's earnings over the current fiscal year (to end-March 2017). As a reminder, in our recent report "Same player shoot again"?, we estimated a valuation between EUR40 (the very minimum, and EUR45 if Vivendi wants to avoid counterbids as far as possible) and EUR51 (maximum) in the event of a takeover bid.

NEXT CATALYSTS

Ubisoft's AGM: on Thursday 29th September. Click here to download

Richard-Maxime Beaudoux, rmbeaudoux@bryangarnier.com

BUY

BG's Wake Up Call

Bryan Garnier stock rating system

For the purposes of this Report, the Bryan Garnier stock rating system is defined as follows:

Stock rating

BUY Positive opinion for a stock where we expect a favourable performance in absolute terms over a period of 6 months from the publication of a recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of

recommendation. This opinion is based not only on the FV (the potential upside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock

will feature an introduction outlining the key reasons behind the opinion.

NEUTRAL Opinion recommending not to trade in a stock short-term, neither as a BUYER or a SELLER, due to a specific set of factors. This view is intended to

be temporary. It may reflect different situations, but in particular those where a fair value shows no significant potential or where an upcoming binary event constitutes a high-risk that is difficult to quantify. Every subsequent published update on the stock will feature an introduction outlining the key

reasons behind the opinion

SELL Negative opinion for a stock where we expect an unfavourable performance in absolute terms over a period of 6 months from the publication of a

recommendation. This opinion is based not only on the FV (the potential downside based on valuation), but also takes into account a number of elements that could include a SWOT analysis, momentum, technical aspects or the sector backdrop. Every subsequent published update on the stock

will feature an introduction outlining the key reasons behind the opinion.

Distribution of stock ratings

BUY ratings 55.8% NEUTRAL ratings 33.1% SELL ratings 11%

Bryan Garnier Research Team

Healthcar Team Pharmaceuticals (Head of Equities) (Head of Equities) 30 (0) 1 56 68 75 33 (0) 1 contained (whead of Equities) deberingaud@bryangamier.com Consumer Team Luxury/Consumer Goods Lois Moran 30 (0) 1 56 68 75 20 (0) (0) (0) (0) (0) (0) (0) (0) (0) (0		<i></i>	<u> </u>	3 3 1 2 2 2	
Nedetch/Biotech Redetch/Biotech Reverages Retailing Antoine Parison Food & Beverages Viginie Roumage	Healthcare Team	Pharmaceuticals		33 (0) 1 56 68 75 33	eleberrigaud@bryangarnier.com
Consumer Team Luxury/Consume Goods Loic Morvan 33 (0) 1 70 36 57 24 Imovan@bryangarnier.com Retailing Antoine Parison 33 (0) 1 70 36 57 03 aparison@bryangarnier.com Luxury/Consumer Goods Cedric Rossi 33 (0) 1 70 36 57 25 cross@bryangarnier.com TMT Video Games / Payments Richard-Maxime Beaudoux 33 (0) 1 56 68 75 22 robusage@bryangarnier.com TMT Palecom Thomas Coudry 33 (0) 1 56 68 75 62 robusadoux@bryangarnier.com Telecom Tomas Coudry 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Utilities Semiconductor Dorian Terral 33 (0) 1 56 68 75 92 deteral@bryangarnier.com Two included of Research (Head of Research) 33 (0) 1 56 68 75 92 deteral@bryangarnier.com Insurance Olivier Pauchaut (Head of Research) 33 (0) 1 56 68 75 92 deteral@bryangarnier.com Though of La Rochebrochaut 33 (0) 1 56 68 75 92 deteral@bryangarnier.com Though of La Rochebrochaut 33 (0) 1 56 68 75 92 deteral@bryangarnier.com Though of La Rochebrochaut 33 (0) 1 56 68 75 92 deteral@bryangarnier.com <th< th=""><th></th><th>Biotech/Medtech</th><th>Mickael Chane-Du</th><th>33 (0) 1 70 36 57 45</th><th>mchanedu@bryangarnier.com</th></th<>		Biotech/Medtech	Mickael Chane-Du	33 (0) 1 70 36 57 45	mchanedu@bryangarnier.com
Retailing Antoine Parison 33 (0) 1 56 68 75 72 nfaes@bryangarnier.com		Medtech/Biotech	Hugo Solvet	33 (0) 1 56 68 75 57	hsolvet@bryangarnier.com
Retailing Antoine Parison 33 (0 1 70 36 57 03 parison@bryangarnier.com Luxury / Consumer Goods Food & Beverages Virginie Roumage 33 (0 1 70 36 57 25 vroumage@bryangarnier.com TMT Video Games / Payments Telecom Thomas Coudry 33 (0 1 56 68 75 22 vroumage@bryangarnier.com Thomas Coudry 33 (0 1 56 68 75 22 vroumage@bryangarnier.com Telecom Thomas Coudry 33 (0 1 56 68 75 26 vroumage@bryangarnier.com Software & IT Services 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Software & IT Services 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Payments 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Utilities Software & Transima 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangarnier.com Pierre-Antoine Chazal 33 (0 1 56 68 75 20 vroumage@bryangar	Consumer Team		Loïc Morvan	33 (0) 1 70 36 57 24	lmorvan@bryangarnier.com
Luxury Consumer Goods Food & Beverages Virginie Roumage 33 (0) 1 56 68 75 22 vroumage@bryangarnier.com TMT Video Games / Payments Telecom Thomas Coudry 33 (0) 1 56 68 75 62 vrouwage@bryangarnier.com Thomas Coudry 33 (0) 1 56 68 75 61 rmbeaudoux@bryangarnier.com Software & IT Services Software & IT Services Dorian Terral 33 (0) 1 56 68 75 91 gramirez@bryangarnier.com Utilities Luxury Telecom Thomas Coudry 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com 33 (0) 1 56 68 75 92 dterral@bryangarnier.com Avier Caroen 33 (0) 1 56 68 75 92 dterral@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 gramirez@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 6		Beverages	Nikolaas Faes	33 (0) 1 56 68 75 72	nfaes@bryangarnier.com
Food & Beverages Virginie Roumage 33 (0) 1 56 68 75 22 voumage@bryangarnier.com TMT Video Games / Payments 33 (0) 1 56 68 75 22 voumage@bryangarnier.com Telecom Thomas Coudry 33 (0) 1 56 68 75 01 voudry@bryangarnier.com Software & IT Services 33 (0) 1 56 68 75 01 voudry@bryangarnier.com Semiconductor Dorian Terral 33 (0) 1 56 68 75 01 vourage@bryangarnier.com Villities Semiconductor Dorian Terral 33 (0) 1 56 68 75 01 vourage@bryangarnier.com Tourance Vierne-Antoine Chazal 33 (0) 1 56 68 75 01 vourage@bryangarnier.com Insurance Vierne-Antoine Chazal 33 (0) 1 56 68 75 01 poachazal@bryangarnier.com Hotels/Business Services Bruno de La Rochebrochard Hotels/Business Services Bruno de La Rochebrochard Software & Iric Lemarié 33 (0) 1 56 68 75 01 poachauf@bryangarnier.com Construction/Infrastructures/Building Materials Eric Lemarié 33 (0) 1 56 68 75 01 poachauf@bryangarnier.com Automotive & Parts Xavier Caroen 33 (0) 1 56 68 75 01 poachauf@bryangarnier.com Software Services Sorvices Sorvice		Retailing	Antoine Parison	33 (0) 1 70 36 57 03	aparison@bryangarnier.com
TMT Payments Richard-Maxime Beaudoux 33 (0) 1 56 68 75 61 mbeaudoux@bryangarnier.com Payments Richard-Maxime Beaudoux 33 (0) 1 70 36 57 04 toudry@bryangarnier.com Rochard Services Richard Regory Ramirez 33 (0) 1 56 68 75 91 gramirez@bryangarnier.com Rochard Payments Avaier Caroen 33 (0) 1 56 68 75 92 dterral@bryangarnier.com Rochard Pierre-Antoine Chazal 33 (0) 1 56 68 75 18 xcaroen@bryangarnier.com Rochard Pierre-Antoine Chazal 33 (0) 1 56 68 75 18 pachazal@bryangarnier.com Rochard Olivier Pauchaut (Head of Research) 33 (0) 1 56 68 75 18 pachazal@bryangarnier.com Rochard Services Bruno de La Rochebrochard 33 (0) 1 56 68 75 18 belarochebrochard@bryangarnier.com Rochard Forstruction/Infrastruct-Fullding Materia Eric Lemarie 33 (0) 1 70 36 57 19 elemarie@bryangarnier.com Rutheting Sophie Braincourt 33 (0) 1 56 68 75 18 braincourt@bryangarnier.com Rochard Payments Sophie Braincourt 33 (0) 1 56 68 75 18 braincourt@bryangarnier.com			Cedric Rossi	33 (0) 1 70 36 57 25	crossi@bryangarnier.com
Payments Telecom Thomas Coudry 33(0) 1 70 36 57 04 toudry@bryangarnier.com Software & IT Services 33 (0) 1 56 68 75 91 gramirez@bryangarnier.com Semiconductor Dorian Terral 33 (0) 1 56 68 75 92 dterral@bryangarnier.com Willities 33 (0) 1 56 68 75 92 dterral@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 18 xcaroen@bryangarnier.com Pierre-Antoine Chazal 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Business Services Pruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Business Services Pruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Business Services Pruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0) 1 56 68 75 92 pachazal@bryangarnier.com Willies Bruno de La Rochebrochard 33 (0)		Food & Beverages	Virginie Roumage	33 (0) 1 56 68 75 22	vroumage@bryangarnier.com
Software & IT Services Semiconductor Dorian Terral Xavier Caroen Pierre-Antoine Chazal Jolivier Pauchaut (Head of Research) Hotels/Business Services Bruno de La Rochebrochard Marketing Xavier Caroen 33 (0) 1 56 68 75 92 dterral@bryangarnier.com Attornotive & Parts Automotive & Parts Sophie Braincourt 33 (0) 1 56 68 75 92 dterral@bryangarnier.com 33 (0) 1 56 68 75 18 pachazal@bryangarnier.com pachazal@bryangarnier.com pachazal@bryangarnier.com pachazal@bryangarnier.com pachazal@bryangarnier.com 33 (0) 1 56 68 75 88 bdelarochebrochard@bryangarnier.com delarochebrochard@bryangarnier.com 33 (0) 1 56 68 75 18 bdelarochebrochard@bryangarnier.com 33 (0) 1 56 68 75 18 bzaroen@bryangarnier.com 34 (0) 1 56 68 75 18 bzaroen@bryangarnier.com 35 (0) 1 56 68 75 18 bzaroen@bryangarnier.com 35 (0) 1 56 68 75 18 bzaroen@bryangarnier.com 35 (0) 1 56 68 75 18 bzaroen@bryangarnier.com 37 (0) 1 56 68 75 18 bzaroen@bryangarnier.com 38 (0) 1 56 68 75 18 bzaro	TMT		Richard-Maxime Beaudoux	33 (0) 1 56 68 75 61	rmbeaudoux@bryangarnier.com
ServicesSemiconductorDorian Terral33 (0) 1 56 68 75 92dterral@bryangarnier.comUtilitiesXavier Caroen33 (0) 1 56 68 75 18xcaroen@bryangarnier.comInsurancePierre-Antoine Chazal33 (0) 1 56 68 75 40pachazal@bryangarnier.comHotels/Business ServicesBruno de La Rochebrochard33 (0) 1 56 68 75 48bdelarochebrochard@bryangarnier.comConstruction/Infrastructures/Building MaterialsEric Lemarié33 (0) 1 70 36 57 17elemarie@bryangarnier.comAutomotive & PartsXavier Caroen33 (0) 1 56 68 75 38xcaroen@bryangarnier.comMarketingSophie Braincourt33 (0) 1 56 68 75 36sbraincourt@bryangarnier.com		Telecom	Thomas Coudry	33(0) 1 70 36 57 04	tcoudry@bryangarnier.com
LitilitiesXavier Caroen33 (0) 1 56 68 75 18xcaroen@bryangarnier.comInsurancePierre-Antoine Chazal33 (0) 1 56 68 75 08pachazal@bryangarnier.comHotels/Business ServicesBruno de La Rochebrochard33 (0) 1 56 68 75 88bdelarochebrochard@bryangarnier.comConstruction/Infrastructures/Building MaterialsEric Lemarié33 (0) 1 70 36 57 17elemarie@bryangarnier.comAutomotive & PartsXavier Caroen33 (0) 1 56 68 75 36xcaroen@bryangarnier.comMarketingSophie Braincourt33 (0) 1 56 68 75 36sbraincourt@bryangarnier.com			Gregory Ramirez	33 (0) 1 56 68 75 91	gramirez@bryangarnier.com
Pierre-Antoine Chazal 33 (0 1 56 68 75 06 pachazal@bryangarnier.com Insurance Olivier Pauchaut (Head of Research) 33 (0 1 56 68 75 48 pauchaut@bryangarnier.com Hotels/Business Services Bruno de La Rochebrochard 33 (0 1 56 68 75 88 bdelarochebrochard@bryangarnier.com Construction/Infrastructures/Building Materials Eric Lemarié 33 (0 1 70 36 57 17 elemarie@bryangarnier.com Automotive & Parts Xavier Caroen 33 (0 1 56 68 75 88 braincourt@bryangarnier.com Marketing Sophie Braincourt 33 (0 1 56 68 75 36 braincourt@bryangarnier.com		Semiconductor	Dorian Terral	33 (0) 1 56 68 75 92	dterral@bryangarnier.com
InsuranceOlivier Pauchaut (Head of Research)33 (0) 1 56 68 75 49pauchaut@bryangarnier.comHotels/Business ServicesBruno de La Rochebrochard33 (0) 1 56 68 75 88bdelarochebrochard@bryangarnier.comConstruction/Infrastructures/Building MaterialsEric Lemarié33 (0) 1 70 36 57 17elemarie@bryangarnier.comAutomotive & PartsXavier Caroen33 (0) 1 56 68 75 18xcaroen@bryangarnier.comMarketingSophie Braincourt33 (0) 1 56 68 75 36sbraincourt@bryangarnier.com	Utilities		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
(Head of Research)Hotels/Business ServicesBruno de La Rochebrochard33 (0) 1 56 68 75 88bdelarochebrochard@bryangarnier.comConstruction/Infrastructures/Building MaterialsEric Lemarié33 (0) 1 70 36 57 17elemarie@bryangarnier.comAutomotive & PartsXavier Caroen33 (0) 1 56 68 75 18xcaroen@bryangarnier.comMarketingSophie Braincourt33 (0) 1 56 68 75 36sbraincourt@bryangarnier.com			Pierre-Antoine Chazal	33 (0) 1 56 68 75 06	pachazal@bryangarnier.com
Construction/Infrastructures/Building MaterialsEric Lemarié33 (0) 1 70 36 57 17elemarie@bryangarnier.comAutomotive & PartsXavier Caroen33 (0) 1 56 68 75 18xcaroen@bryangarnier.comMarketingSophie Braincourt33(0) 1 56 68 75 36sbraincourt@bryangarnier.com	Insurance			33 (0) 1 56 68 75 49	opauchaut@bryangarnier.com
Automotive & Parts Xavier Caroen 33 (0) 1 56 68 75 18 xcaroen@bryangarnier.com Marketing Sophie Braincourt 33(0) 1 56 68 75 36 sbraincourt@bryangarnier.com	Hotels/Business Services		Bruno de La Rochebrochard	33 (0) 1 56 68 75 88	bdel ar och ebroch ard @bryang arnier.com
Marketing Sophie Braincourt 33(0) 1 56 68 75 36 sbraincourt@bryangarnier.com	Construction/Infrastructures/Building Materials		Eric Lemarié	33 (0) 1 70 36 57 17	elemarie@bryangarnier.com
·	Automotive & Parts		Xavier Caroen	33 (0) 1 56 68 75 18	xcaroen@bryangarnier.com
Market Data & Information Systems ManagerEric Monnier33(0) 1 56 68 75 63emonnier@bryangarnier.com	Marketing		Sophie Braincourt	33(0) 1 56 68 75 36	sbraincourt@bryangarnier.com
	Market Data & Information	n Systems Manager	Eric Monnier	33(0) 1 56 68 75 63	emonnier@bryangarnier.com

A copy of the Bryan Garnier & Co Limited conflicts policy in relation to the production of research is available at www.bryangarnier.com

London

Beaufort House 15 St. Botolph Street London EC3A 7BB

Tel: +44 (0) 207 332 2500 Fax: +44 (0) 207 332 2559 Authorised and regulated by the Financial Conduct Authority (FCA)

Paris

26 Avenue des Champs Elysées 75008 Paris

Tel: +33 (0) 1 56 68 75 00 Fax: +33 (0) 1 56 68 75 01 Regulated by the

Financial Conduct Authority (FCA) and the Autorité de Contrôle prudential et de resolution (ACPR)

New York

750 Lexington Avenue New York, NY 10022 Tel: +1 (0) 212 337 7000 Fax: +1 (0) 212 337 7002 FINRA and SIPC member

Munich

Widenmayerstrasse 29 80538 Munich Germany +49 89 2422 62 11



Disclaimer:

Bryan Garnier & Co Limited, registered in England Number 03034095 with registered office: Beaufort House 15 St Botolph Street, London EC3A 7BB, United Kingdom and its MIFID branch registered in France Number 452 605 512 with registered office: 26, Avenue des Champs Elysées 75008 Paris, France. Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority (Firm Reference Number 178733) and is a member of the London Stock Exchange.

This Report may not be reproduced, distributed or published by you for any purpose except with the Firms' prior written permission. The Firm reserves all rights in relation to this Report.

Past performance information contained in this Report is not an indication of future performance. The information in this report has not been audited or verified by an independent party and should not be seen as an indication of returns which might be received by investors. Similarly, where projections, forecasts, targeted or illustrative returns or related statements or expressions of opinion are given ("Forward Looking Information") they should not be regarded as a guarantee, prediction or definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and will differ from assumptions. A number of factors, in addition to the risk factors stated in this Report, could cause actual results to differ materially from those in any Forward Looking Information.

Important information - This report may contain "Independent" and "Corporate/Non-independent" research reports.

Unless stated otherwise, documents in this report are classified under the FCA Handbook as being investment research (independent research). Bryan Garnier & Co Limited has in place the measures and arrangements required for investment research as set out in the FCA's Conduct of Business Sourcebook.

Independent investment research reports:

Independent investment research reports are prepared by Bryan Garnier & Co Limited and are distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports are provided for information purposes only and do not constitute an offer, or a solicitation of an offer, to buy or sell relevant securities, including securities mentioned in this Report and options, warrants or rights to or interests in any such securities. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person. The information and opinions contained in these reports have been compiled from and are based upon generally available information which the Firm believes to be reliable but the accuracy of which cannot be guaranteed. All components and estimates given are statements of the Firm, or an associated company's, opinion only and no express representation or warranty is given or should be implied from such statements. All opinions expressed in these reports are subject to change without notice. To the fullest extent permitted by law neither the Firm nor any associated company accept any liability whatsoever for any direct or consequential loss arising from the use of these reports. Information may be available to the Firm and/or associated companies which is not reflected in these reports. The Firm or an associated company may have a consulting relationship with a company which is the subject of these reports.

Corporate or Non-Independent investment research reports:

Non-independent research reports are prepared by Bryan Garnier & Co Limited and are being distributed only to clients of Bryan Garnier & Co Limited (the "Firm"). Bryan Garnier & Co Limited is authorised and regulated by the Financial Conduct Authority ("FCA") and is a member of the London Stock Exchange.

These reports have been sent to you for marketing purposes only and are non-independent research within the meaning of the FCA rules. These reports are not being held out as an objective or independent explanation of the matters contained in them and should not be treated as such. These reports have not been prepared in accordance with the legal requirements designed to promote the independence of investment research. The Firm is not subject to any prohibition on dealing ahead of the dissemination of investment research. These reports usually focus on emerging European growth companies. The contents of these reports as well as the other research documents on emerging growth stocks do not contain the Firm's usual stock ratings. The intrinsic value analysis is presented to provide a framework for stock valuation and discussion, and represents an estimated value on the date of publishing, which may be subject to change without notice.

The Firm's rationale for not having ratings on the stock includes the fact that such stock may have limited market capitalisation and liquidity and while the Firm may express an opinion on the near-term movement of the stock, what action investors should take depends on many factors, including liquidity/risk tolerance, holdings timeframe and investment philosophy. Emerging companies evolve rapidly with a continuous flow of information that can significantly impact the company and in the Firm's opinion this cannot be reflected by a periodic rating. Additionally, the Firm may have an advisory relationship with the company which is the subject of these reports, including for the production of sponsored research, and may expect to receive or intend to seek compensation for investment banking services from that company in the six months following the date of these reports.

To the fullest extent permitted by law, the Firm does not accept any liability whatsoever for any direct or consequential loss arising from any use of the information contained in these reports. Information may be available to the Firm which is not reflected in these reports. They are provided for information purposes only and do not constitute an offer or solicitation to buy or sell any of the securities discussed in them. These reports are for general circulation to clients of the Firm and as such are not, and should not be construed as, investment advice or a personal recommendation. No account is taken of the investment objectives, financial situation or particular needs of any person.

Disclosures specific to clients in the United Kingdom

This Report has not been approved by Bryan Garnier & Co Limited for the purposes of section 21 of the Financial Services and Markets Act 2000 because it is being distributed in the United Kingdom only to persons who have been classified by Bryan Garnier & Co Limited as professional clients or eligible counterparties. Any recipient who is not such a person should return the Report to Bryan Garnier & Co Limited immediately and should not rely on it for any purposes whatsoever.

Notice to US investors

This research report (the "Report") was prepared by Bryan Garnier & Co Limited for information purposes only. The Report is intended for distribution in the United States to "Major US Institutional Investors" as defined in SEC Rule 15a-6 and may not be furnished to any other person in the United States. Each Major US Institutional Investor which receives a copy of this Report by its acceptance hereof represents and agrees that it shall not distribute or provide this Report to any other person. Any US person that desires to effect transactions in any security discussed in this Report should call or write to our US affiliated broker, Bryan Garnier Securities, LLC. 750 Lexington Avenue, New York NY 10022. Telephone: 1-212-337-7000. This Report is based on information obtained from sources that Bryan Garnier & Co. Ltd. believes to be reliable and, to the best of its knowledge, contains no misleading, untrue or false statements but which it has not independently verified. Neither Bryan Garnier & Co. Ltd. and/or Bryan Garnier Securities LLC make no guarantee, representation or warranty as to its accuracy or completeness. Expressions of opinion herein are subject to change without notice. This Report is not an offer to buy or sell any security.

Bryan Garnier Securities, LLC and/or its affiliate, Bryan Garnier & Co Limited may own more than 1% of the securities of the company(ies) which is (are) the subject matter of this Report, may act as a market maker in the securities of the company(ies) discussed herein, may manage or co-manage a public offering of securities for the subject company(ies), may sell such securities to or buy them from customers on a principal basis and may also perform or seek to perform investment banking services for the company(ies).

Bryan Garnier Securities, LLC and/or Bryan Garnier & Co Limited are unaware of any actual, material conflict of interest of the research analyst who prepared this Report and are also not aware that the research analyst knew or had reason to know of any actual, material conflict of interest at the time this Report is distributed or made available....